GC-MS Profiling and In Silico Studies to Identify Potential SARS-CoV-2 Nonstructural Protein Inhibitors from Psidium guajava
Keywords:
Docking, GC-MS, Leaves, P. guajava, SARS-CoV-2Abstract
The COVID-19 pandemic, caused by the SARS-CoV-2, has prompted international concern. The aim of this study is to identify SARS-CoV-2 nonstructural protein inhibitors-potentially bioactive phytocompounds from the traditional plant Psidium guajava. GC-MS analysis of P. guajava methanol leaves was investigated. In silico molecular docking, drug-likeness, toxicity, and prediction of the compounds’ substance activity spectra (PASS) were evaluated. GC-MS analysis identified thirty (30) phytocompounds. According to molecular docking, all the phytocompounds have strong binding energies. The phytocompound beta bisabolene gave the best binding affinity of -5.0 kcal/mole. The detected compounds were all in accordance with Lipinski’s Rule of Five (RO5). This showed that the identified P. guajava compounds would have lower attrition rates during clinical trials and thus have a better chance of being marketed. According to this research, a potential COVID-19 drug could be created using the newly identified
phytocompounds of P. guajava.

Published
How to Cite
Issue
Section
Copyright (c) 2022 Ifeanyi Edozie Otuokere, Onyinye Uloma Akoh, Felix Chigozie Nwadire, Chinedum Ifeanyi Nwankwo, Joy Nwachukwu Egbucha, Chiemela Wisdom, Ogbonna Augustine Okwudiri

This work is licensed under a Creative Commons Attribution 4.0 International License.
African Scientific Reports (ASR) is published under the Creative Commons Attribution 4.0 International License. This license was developed to facilitate open access, namely, it allows articles to be freely downloaded and to be re-used and re-distributed without restriction, as long as the original work is correctly cited. More specifically, anyone may copy, distribute or reuse these articles, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article, mine the article even for commercial purposes, as long as they credit the author(s).